Despite the company's improved revenue, industry growth proj...
Despite the company's improved revenue, industry growth projection is significantly higher. Elevated P/S ratio and high stock price, based on business turnaround hopes, suggest potential overvaluation risk.
GuangYuYuan Chinese Herbal Medicine Co., Ltd.'s (SHSE:600771) Share Price Not Quite Adding Up
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment